MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
Aravive Total Liabilities 2011-2026 | ARAV
Annual Total Liabilities Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.5 M | 25.6 M | 19.7 M | 13.1 M | 9.52 M | 11 M | 54.5 M | 8.83 M | 6.92 M | 3.98 M | 7.28 M | 2.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 54.5 M | 2.2 M | 17.8 M |
Quarterly Total Liabilities Aravive
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.3 M | 45.6 M | 81.7 M | 51.5 M | 27.2 M | 25.8 M | 34.7 M | 25.6 M | 22.5 M | 21.2 M | 18.6 M | 19.7 M | 19.7 M | 19.7 M | 19.7 M | 13.1 M | 13.1 M | 13.1 M | 13.1 M | 9.52 M | 9.52 M | 9.52 M | 9.52 M | 11 M | 11 M | 11 M | 11 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 8.83 M | 8.83 M | 7.31 M | 7.82 M | 6.92 M | 4.29 M | 6.92 M | 6.92 M | 4.48 M | 4.48 M | 4.48 M | 4.48 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 81.7 M | 4.29 M | 20.3 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
395 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
5.38 M | - | 4.01 % | $ 150 M |  Canada |
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
13.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Albireo Pharma
ALBO
|
126 M | - | -0.23 % | $ 916 M | USA |
 |
Adagene
ADAG
|
38.7 M | $ 2.83 | -2.75 % | $ 159 M |  China |
 |
Biogen
BIIB
|
11.3 B | $ 177.27 | 0.62 % | $ 25.8 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
855 M | $ 81.19 | -0.98 % | $ 1.57 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Amgen
AMGN
|
50 B | $ 339.82 | -0.91 % | $ 182 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
90.7 M | - | - | $ 1.01 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
BioNTech SE
BNTX
|
3.12 B | $ 114.47 | -1.97 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 9.65 | -0.16 % | $ 1.52 B |  Britain |
 |
Midatech Pharma plc
MTP
|
6.46 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Aytu BioScience
AYTU
|
93.3 M | $ 2.56 | -0.78 % | $ 16.1 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 3.23 | -0.92 % | $ 7.77 B |  Australia |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
CASI Pharmaceuticals
CASI
|
30.3 M | $ 0.99 | - | $ 135 M | USA |
 |
Catalyst Biosciences
CBIO
|
38.1 M | $ 10.0 | -1.43 % | $ 658 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
Cerus Corporation
CERS
|
144 M | $ 2.3 | -1.08 % | $ 424 M | USA |
 |
Aptose Biosciences
APTO
|
14.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cellectis S.A.
CLLS
|
253 M | $ 3.81 | -4.51 % | $ 116 M | France |
 |
Brickell Biotech
BBI
|
6.5 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Beam Therapeutics
BEAM
|
370 M | $ 28.26 | -3.52 % | $ 2.33 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
1.29 B | $ 223.79 | -0.07 % | $ 5 B |  Danmark |
 |
Athira Pharma
ATHA
|
13.9 M | - | - | $ 269 M | USA |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
106 M | $ 68.89 | -0.33 % | $ 9.21 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
124 M | $ 24.53 | -0.2 % | $ 2.91 B | USA |
 |
Cardiff Oncology
CRDF
|
14.2 M | $ 1.68 | 3.75 % | $ 80.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
21.9 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
6.61 M | - | -10.17 % | $ 12.2 K | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
243 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
84 M | - | -7.31 % | $ 87 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 4.03 | -1.71 % | $ 8.77 B |  Israel |
 |
Amneal Pharmaceuticals
AMRX
|
3.32 B | $ 13.77 | -2.45 % | $ 4.25 B | USA |
 |
AIkido Pharma
AIKI
|
7.27 M | - | 1.93 % | $ 17.4 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
5.4 M | - | -74.18 % | $ 955 K | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
28.4 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
107 M | - | - | $ 2.17 B | USA |